Ru JiaRuJia

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. on its US$174 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.* This transaction was named “Best IPO - Hong Kong SAR” by Finance Asia Achievement Awards 2023.*

Yunkang Group Limited, a leading medical operation service provider in China that offers a full suite of diagnostic testing services for medical institutions, on its approximately US$140 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.*

Arrail Group Limited, the largest dental services provider in the premium private dental service market in China by revenue, on its global offering and IPO on the Main Board of the Hong Kong Stock Exchange.*

Goldman and CICC as the joint sponsors and underwriters on the US$1.52 billion global offering and dual primary listing of Li Auto Inc on the Main Board of the Hong Kong Stock Exchange.*

Zhaoke Ophthalmology Limited, a spin-off of Lee’s Pharmaceutical Holdings Limited, on its US$270 million global offering and listing on the Hong Kong Exchanges and Clearing Limited. Goldman Sachs (Asia) L.L.C. and Jefferies Hong Kong Limited were joint sponsors and joint representatives for this IPO.*

MicroPort CardioFlow Medtech Corporation, a medical device company in China focusing on the research, development, and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases, on its US$322 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange. The listing is a spin-off from Hong Kong-listed MicroPort Scientific Corporation.*

Mediwelcome Healthcare Management & Technology Inc., a provider of integrated healthcare marketing solutions in China, on its HK$89.3 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.*

Alphamab Oncology, a leading clinical-stage biopharmaceutical company in China, on its US$234 million initial public offering listed on the Main Board of The Stock Exchange of Hong Kong.*

CMS and CITICS as the joint sponsors and underwriters on the HK$975 million (US$125.74 million) global offering and listing of Strawbear Entertainment Group, a major drama series producer and distributor in China, covering the investment, development, production, and distribution of TV and web series, on the Main Board of the Hong Kong Stock Exchange.*

China Bright Culture Group, a rapidly growing independent producer of variety programs in China, on its US$116 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.*

Rizhao Port Jurong Co., Ltd., the largest port for grain and woodchip imports in China and a subsidiary of Rizhao Port Co., Ltd., on its US$69.65 million global offering and listing of its H shares on the Main Board of the Hong Kong Stock Exchange.*

CICC, BofA, CMBI, Fosun Hani and Citi as the joint sponsors and underwriters on the US$397.4 million global offering and listing of Shanghai Henlius Biotech, Inc. on the Main Board of the Hong Kong Stock Exchange. The listing is a dual-level spin-off from Hong Kong-listed Fosun International and A+H-listed Fosun Pharma.*

Advising the following companies on various post-listing compliance matters: Haidilao International Holding Ltd, Super Hi International Holdings Ltd., Arrail Group Limited., Yunkang Group Limited., MicroPort CardioFlow Medtech Corporation and CanSino Biologics Inc.*

Edding Group Company Limited, an integrated biopharmaceutical company, in connection with a proposed merger and reverse takeover with Genor Biopharma Holdings Limited, a Hong Kong-listed biopharmaceutical company under Chapter 18A. The deal represents the first ever reverse takeover relating to a Chapter 18A listed company. This transaction was named “Deals of the Year 2024” by China Business Law Journal and “M&A Deal of the Year 2025” by ALB China Awards.*